Libtayo plus Platinum-Based Chemotherapy Now FDA Approved for NSCLC without Genomic Aberrations

JHOP - December 2022 Vol 12, No 6 - FDA Oncology Update
NEW INDICATIONS/DOSING

On November 8, 2022, the FDA approved a new indication for cemiplimab-rwlc (Libtayo; Regeneron), a PD-1 inhibitor, in combination with platinum-based chemotherapy, for the treatment of adults with advanced non–small-cell lung cancer (NSCLC) and no EGFR, ALK, or ROS1 aberrations.

Libtayo was previously approved for first-line treatment of advanced or metastatic NSCLC with PD-1 expression of ≥50% but with no EGFR, ALK, or ROS1 aberrations, in addition to the treatment of cutaneous squamous-cell carcinoma and basal-cell carcinoma.

The FDA approved this new indication based on results of Study 1611, a randomized, multicenter, multinational, double-blind, active-controlled clinical trial of 466 patients with advanced NSCLC who had not received systemic treatment.

The patients were randomized in a 2:1 ratio to cemiplimab plus platinum-based chemotherapy every 3 weeks for 4 cycles, followed by cemiplimab and maintenance chemotherapy, or to placebo plus platinum-based chemotherapy every 3 weeks for 4 cycles, followed by placebo and maintenance chemotherapy.

“Clearly, this is an advance which is clinically meaningful for our patients with advanced stage non–small-cell lung cancer,” said David R. Gandara, MD, Director, Thoracic Oncology Program, University of California Davis Comprehensive Cancer Center, Sacramento.

The main efficacy measure was overall survival (OS). Additional measures were progression-free survival (PFS) and overall response rate (ORR).

Cemiplimab plus chemotherapy demonstrated significant and clinically meaningful improvement in OS versus placebo plus chemotherapy (hazard ratio [HR], 0.71; 95% confidence interval [CI], 0.53-0.93; 2-sided P = .0140). The median OS was 21.9 months (95% CI, 15.5-not evaluable) with cemiplimab plus chemotherapy and 13 months (95% CI, 11.9-16.1) with placebo plus chemotherapy. The median PFS was 8.2 months (95% CI, 6.4-9.3) in the cemiplimab arm versus 5 months (95% CI, 4.3-6.2) in the placebo arm (HR, 0.56; 95% CI, 0.440.70; P <.0001). The ORR was 43% (95% CI, 38-49) and 23% (95% CI, 16-30), respectively.

The most common (≥15%) adverse events in the study were alopecia, musculoskeletal pain, nausea, fatigue, peripheral neuropathy, and decreased appetite.

Related Items
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Web Exclusives published on February 12, 2024 in FDA Oncology Update
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 19, 2023 in FDA Oncology Update
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
JHOP - December 2023 Vol 13, No 6 published on November 17, 2023 in FDA Oncology Update
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
JHOP - December 2023 Vol 13, No 6 published on November 3, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: